-

Scipher Medicine® to Present at the Jeffries London Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Scipher Medicine, a precision immunology company matching patients with their most effective therapies, today announced that Alif Saleh, Chief Executive Officer, and John Strumbos, Chief Financial Officer, will participate in the Jeffries London Healthcare Conference, November 16-19.

Scipher Medicine will present from London at 10 a.m. GMT on Tuesday, November 16, and management will be available for in-person and virtual investor meetings during the conference. A live webcast of the conference presentation will be available here.

About Scipher Medicine®

Scipher Medicine, a precision immunology company matching patients with their most effective therapies, believes that patients deserve simple answers to treatment options based on scientifically backed data. Using spectra™, our proprietary network medicine platform, and artificial intelligence, we commercialize blood tests revealing a person’s unique molecular disease signature and match it to the most effective therapy, ensuring optimal treatment from day one. The patient molecular data generated from our tests further supports the discovery and development of novel and more effective therapeutics. We partner with leading payers, providers, and pharmaceutical companies to bring precision medicine to autoimmune diseases. Visit http://www.sciphermedicine.com and follow Scipher Medicine on Twitter, Facebook, and LinkedIn.

Contacts

Scipher Medicine:
Media Relations
Matt Burns
VP, Head of Communications
PR@scipher.com
518-423-5907

Investor Relations
John Strumbos, Ph.D., MBA
Chief Financial Officer
IR@scipher.com

Scipher Medicine


Release Versions

Contacts

Scipher Medicine:
Media Relations
Matt Burns
VP, Head of Communications
PR@scipher.com
518-423-5907

Investor Relations
John Strumbos, Ph.D., MBA
Chief Financial Officer
IR@scipher.com

Social Media Profiles
More News From Scipher Medicine

Nearly 15% of Prescribing U.S. Rheumatologists Use Scipher Medicine’s PrismRA® Blood Test Since Its Launch A Year Ago

WALTHAM, Mass.--(BUSINESS WIRE)--Scipher Medicine, a precision immunology company matching patients with their most effective therapy, today announced that nearly 15 percent of prescribing U.S. rheumatologists have used PrismRA since its launch a year ago, resulting in lowered healthcare costs and improved patient outcomes. PrismRA is the only blood test in the market informing personalized treatment decisions for patients with rheumatoid arthritis (RA). Even though there are five commonly pres...

Scipher Medicine Appoints Dr. Michael Elliott to its Science Advisory Board

WALTHAM, Mass.--(BUSINESS WIRE)--Scipher Medicine, a precision immunology company matching patients with their most effective therapy, today announced the appointment of Michael Elliott, MBBS, PhD, FRACP, as scientific advisor. Dr. Elliott is a physician-scientist and pioneer in drug development for autoimmune diseases. Dr. Elliott’s career spans 25 years including his role as senior vice president of Immunology at Janssen Pharmaceuticals, a Johnson & Johnson company, where he led the clini...

Scipher Medicine® Appoints Sam Asgarian, M.D., MBA Chief Medical Officer

WALTHAM, Mass.--(BUSINESS WIRE)--Scipher Medicine, a precision immunology company matching patients with their most effective medication therapies, today announced the appointment of Sam Asgarian, M.D., MBA, as chief medical officer. “We are thrilled to welcome Dr. Asgarian to our leadership team,” said Alif Saleh, chief executive officer of Scipher Medicine. “His strong blend of experience as a health care clinician and business leader will serve us well as we pursue our critical mission.” Dr....
Back to Newsroom